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Molecular mimicryr histocompatibility complex (MHC) is a gene-rich region of about 7.6 Mb on
chromosome 6, and includes a high proportion of genes involved in the immune response. Among these are
the two Human Leukocyte Antigen (HLA) gene clusters, class I and class II, which encode highly polymorphic
classical HLA-A, B, C and HLA-DR, DQ and DP genes, respectively. The protein products of the classical HLA
genes are heterodimeric cell surface molecules that bind short peptides derived from non-self and self
proteins, including infections and auto-antigens. The presentation of these HLA-anchored peptides to T
lymphocytes triggers a cascade of responses in immune-associated genes that leads to adaptive immunity.
Associations between HLA class II alleles and childhood leukemia have been reported in a number of studies.
This could be due to the role of HLA allele-restricted peptide binding and T cell activation, or linkage
disequilibrium to an MHC-linked “leukemia gene” in the pathogenesis of childhood leukemia. Efforts are
currently in progress to resolve these questions, using large leukemia case-control sample series such as the
UK Childhood Cancer Study (UKCCS) and the Northern California Childhood Leukemia Study (NCCLS). Here
we review the background to these studies, and present a novel hypothesis based on the paradigm of HLA-
associated auto-immune disease that might explain an infection-based etiology of childhood leukemia.
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Leukemia is the most common malignant disease among children
under the age of 15 years in socio-economically developed parts of the
world, including Europe, North America, and Australasia [1,2]. Despite
considerable phenotypic and genetic diversity, the numerically
dominant leukemia subtype is B cell precursor (BCP) ALL which hasMary's Hospital, Manchester,
lor).
NC-ND license.a characteristic but unexplained age-incidence peak between 2 and
5 years of age [3]. Cytogenetic and molecular analyses have revealed
that leukemia cells carry non-random chromosome rearrangements
juxtaposing or amplifying genes associated with leukemia initiation
[4]. In BCPALL, two types of rearrangement account for N50% of cases:
∼25% of patients carry a reciprocal translocation between chromo-
somes 12 and 21 [t(12;21)(12p13;21q22)], leading to the in-frame
fusion of the TEL (ETV6) gene on chromosome 12p13 and the AML1
(RUNX1) gene on 21q22, respectively. A further 30% of cases have a
high hyperdiploid (HeH) karyotype, where the modal chromosome
number, characterized by non-random gain of chromosomes X, 4, 6, 8,
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initiating rearrangements are necessary, but not sufﬁcient, to give rise
to clinical leukemia [4]. In BCP ALL, progression from pre-leukemia to
overt clinical disease requires additional genetic lesions which are
thought to be acquired under the inﬂuence of an abnormal, usually
post-natal, immune response to infection [5].
There has been much debate about the type and mechanism of
infectious causation in childhood leukemia prompted by the failure to
date to detect a causative infectious agent [5–7]. Molecular evidence
has shown that the frequency of children with leukemia-initiating
chromosomal rearrangements at birth exceeds the number develop-
ing clinical leukemia by two orders of magnitude [8], and are not
increased following exposure of the pre-term newborn to diagnostic
radiation [9]. This suggests that progression from pre-leukemia to
clinical disease involves transition through a bottleneck inﬂuenced by
the timing of exposure to post-natal infection. Paradoxically, early
exposure to infection seems to confer protection, whilst delayed
exposure is thought to lead to an aberrant immune response
facilitating progression to leukemia [5]. Whilst this “second-hit”
seems to require the lapse of sufﬁcient time to accumulate additional
somatic mutations, it is not yet clear whether the infection conferring
protection following early exposure also leads to increased risk if
exposure is delayed. Here we review some of the recent studies on the
role of the human major histocompatibility complex (MHC) in the
etiology of childhood leukemia, and propose a novel hypothesis for
infectious causation.
The human major histocompatibility complex
In the absence of direct evidence for the role of an infectious agent
in childhood leukemia, our interests have focused on proxy measures
of immunity to infection that can be attributed to genetically-
determined differences in immune function. Central to these studies
are the genes of the human MHC, and speciﬁcally the Human
Leukocyte Antigen (HLA) genes.Fig. 1. Schematic map (not to scale) of the extended humanMHC (xMHC) on the short (p) arm
class I genes, HLA-A, B and C, and is located telomeric of the class III region. The HLA classThe extended human major histocompatibility complex (xMHC) on
the short arm of chromosome 6 (6p21.3) spans about 7.6 megabase DNA
[10]. It includes 421 loci, of which 252 are expressed, and is partitioned
into the class I, II and III regions, the class III region being locatedbetween
I and II, and the most gene-dense region of the human genome (Fig. 1).
The MHC contains a number of clustered and duplicated genes, the
foremost of which are theHLA class I and class II gene clusters. The class I
gene cluster includes the highly polymorphic expressed classical HLA-A,
B andC genes; the class II gene cluster includes the polymorphic classical
HLA-DR, DQ and DP genes. Both gene clusters encode cell surface
heterodimeric proteins whose primary function is to bind short peptide
fragments derived from non-self and self proteins in a closed (class I) or
open (class II)-ended peptide binding groovewhosewalls are formed by
two alpha helices, the ﬂoor consisting of a beta-pleated sheet. Peptides
anchored to class I molecules are targeted by the Tcell receptors (TCR) of
CD8+ cytotoxic Tcells; those boundby class IImolecules are presented to
and activate CD4+ T cells [11]. In both cases, the secure anchoring of
peptides (T cell epitopes) by an HLA allotypic molecule is an absolute
requirement for the formation of a tri-molecular TCR–peptide–HLA
complex leading to T cell activation. This binding is inﬂuenced by the
charge and size characteristics of a series of polymorphic peptidebinding
pockets lining the peptide or antigen-binding groove of the HLA
molecule. The afﬁnity of a given antigenic peptide for a polymorphic
HLA allotype enables T cells to constantly sample the individual's
antigenic environment for the presence of pathogens requiring a speedy
protective immune response to eliminate the pathogen. Rapid evolution
of pathogen sequences is thought to have exerted the signiﬁcant
selective forces that have given rise to the extremely high level of HLA
polymorphisms in the population [12]. However, there is considerable
ﬂexibility and overlap in peptide binding between allotypes, due to the
sharing of peptide pocket polymorphisms between alleles, leading to
within-locus HLA allele clusters known as supertypes [13]. Despite this
overlap in the speciﬁcity of peptide binding, a relatively small number
(4–6) of peptide binding pockets impose constraints on peptide
sequences that can be accommodated by HLA molecules [14]. It wouldof human chromosome 6. The HLA class I gene cluster includes the 3 expressed classical
II gene cluster is located centromeric of the HLA class III region.
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immune response gene cascade; however, the formation of a TCR–
peptide–HLA tri-molecular complex is at the epicenter of T cell
interactions with non-self and self antigens, and probably holds the
answers to many HLA-associated diseases [11]. Thus HLA allele
associations with childhood leukemia are likely to provide important
insights into the role of infection in progression from pre-leukemia to
clinical disease.
In addition to the HLA genes, the xMHC includes some 67 other
genes, comprising about 28% of expressed MHC genes, that are
involved in either adaptive or innate immunity [10]. These include the
genes of the immunoglobulin superfamily, inﬂammation-associated
genes, such as tumor necrosis factor and lymphotoxin, leukocyte
maturation, complement genes, non-classical HLA genes, and immune
regulation and stress response genes. Furthermore, the region also
contains a large number of genes not related to the immune system
that play a role in cell cycle regulation, apoptosis, transcription and
translational machinery, signaling, and other cellular processes.
Although a detailed discussion of gene function is beyond the scope
of this review, none of these MHC genes can yet be excluded as
candidates in childhood leukemia susceptibility.
The MHC and childhood leukemia
Historically, the clinical signiﬁcance of the HLA genes is their role
as a barrier to the free exchange of organs and tissues between
individuals. However, it is now clear that the primary biological
function of HLA genes is the orchestration of the immune response to
pathogens through the formation of TCR–peptide–HLA complexes.
The fact that the HLA genes are associated with more diseases than
any other region of the genome may reﬂect a common underlying
pathogenetic pathway in which sub-version of the immune response
can arise as a consequence of interactions between infection or other
non-self antigens and HLA molecules. It is thus noteworthy that the
majority of HLA-associated diseases have an autoimmune pathogen-
esis [12] possibly caused by the triggering of cross-reactive T cell
responses to self proteins by pathogens. The breakdown of immune
tolerance to self as a result of exposure to infection, leading to the
destruction of self tissues recognized as auto-immune disease, has
been termed molecular or pathogen mimicry and may be an
underlying characteristic of many HLA-associated diseases [15]. In
this paper, we consider how molecular mimicry might inﬂuence the
risk of childhood leukemia in the context of an infectious etiology.
Prompted by the work of Lilly and colleagues in the 1960s showing
that susceptibility to Gross retroviral leukemia in the mouse was linked
to the H-2 complex [16,17], childhood leukemia was one of the ﬁrst
human diseases to be investigated for associations with HLA antigens.
These early studies focused on HLA class I antigens, but produced
inconsistent results [18], probably due to small patient numbers
inﬂuenced by selection, limited diagnostic criteria, and the use of
serological HLA typing methods. Later studies of the HLA-D or class II
region using serological typing suffered from the same problems, but
suggested an association between class II alleles and survival [19].
By the 1990s, radical improvements in the diagnostic classiﬁcation
and treatment of childhood leukemias, better survival rates, and
progress in the design of molecular epidemiological studies made it
possible to re-examine the relationship between HLA and childhood
leukemia. Importantly, the development of high resolution molecular
typing methods driven by the needs of donor-recipient hematopoietic
stem cell transplantation [20] made it possible to analyze inter-
individual differences in the key antigen-binding sites ofHLA alleles as
a proxy measure of interactions with foreign (and self) peptides. More
recent developments in high-throughput single nucleotide poly-
morphism (SNP) genotyping have extended this capability to the
identiﬁcation of conserved haplotype blocks across the entire xMHC
[21] which should allow the construction of a detailed MHC map tolocalize all MHC-associated childhood leukemia genes, as recently
demonstrated for type 1 diabetes [22]. Ultimately, the dual strategy of
identifying the functional contribution of HLA alleles in the causation
of childhood leukemia, and mapping of additionally important MHC
genes will help to pinpoint the role of infection, and enable progress to
be made toward the elusive goal of childhood leukemia prevention.
Conﬁrmation of many HLA associations with a diversity of diseases
has nevertheless proven to be extremely challenging, even in
relatively common auto-immune diseases [23]. These challenges can
largely be attributed to methodologic issues related to between-study
heterogeneity in case deﬁnition, selection bias, statistical power to
detect associations, and confounding due to population stratiﬁcation.
Additionally, the high levels of linkage disequilibrium (the non-
random association between alleles of different genetic loci) within
the MHC, giving rise to extended haplotypes, can make it difﬁcult to
identify theMHC genes primarily responsible for disease [24,25]. This
is further complicated by the observation that linkage disequilibrium
differs to varying degrees between race/ethnicity groups [21],
emphasizing the critical nature of identifying racially homogenous
study populations and implementing adjustment methods to account
for differences in genetic structure.
In this paper, we describe recent and ongoing work that has been
initiated to elucidate the role of the xMHC in childhood leukemia
etiology using data and biospecimens from two large population-
based case-control studies, the United Kingdom Childhood Cancer
Study (UKCCS) and the Northern California Childhood Leukemia Study
(NCCLS). The UKCCS was a carefully designed population-based case-
control study set up in 1992, largely in response to societal concerns
about the role of certain environmental carcinogens in the causation
of childhood cancer and leukemia in the UK [26]. A key issue for
consideration by the UKCCS was the perceived intrinsic vulnerability
of parental germ cells, the fetus and newborn to changing patterns of
radiation, and chemical carcinogen exposure and infection. A back-
drop to the study, organized under the aegis of the UK Coordinating
Committee on Cancer Research (UKCCCR), was the provocative
suggestion, by Gardner et al. [27], that the Seascale leukemia cluster
associated with the nuclear reprocessing plant at Sellaﬁeld, may have
arisen by radiation-induced germ-line mutation. The need to address
this and a number of other compelling hypotheses led to the initiation
of this 5-year nationwide study [26].
Initiated in 1995, the NCCLS is a major ongoing US-based
population-based case-control study which was also designed to
investigate environmental and genetic causes of childhood leukemia
largely in response to the large number of childhood cancer clusters
that came to public attention, requiring investigation by health
authorities [28]. Incident childhood leukemia cases are ascertained
from major pediatric centers serving the 35-county Northern and
Central California study area. Controls are randomly selected from the
birth certiﬁcate ﬁles and matched to cases on date of birth, gender,
maternal race, and Hispanic status. Among the vast amount of
exposure data collected are detailed accounts of childhood infections,
child's vaccination history, family structure, number of siblings and
day-care and other school attendance. These data were obtained with
special emphasis on exposure during time windows of development.
Biospecimens collected in the NCCLS include constitutive DNA
specimens from buccal cell scrapings and saliva, as well as pre-
treatment blood and bone marrow from case subjects.
Reverse immunogenetics and molecular mimicry (UKCCS)
One of the major difﬁculties in establishing an etiological role for
infection in childhood leukemia has been in the identiﬁcation of a
causal agent. A child is exposed to a blizzard of infection and allergen-
derived antigenic peptides during the early post-natal period, many of
which will have been cleared by the immune system before the
development of childhood leukemia.Whilst it is technically possible to
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of previous encounters with infection in children, this is logistically
difﬁcult in the prodromal phase of childhood leukemia. The
alternative is to use reverse immunogenetics – the HLA component
of the tri-molecular complex – to answer this question. Reverse
immunogenetics aims to identify the peptide “footprint” of the HLA
allele associated with disease (childhood leukemia) in order that this
can be used to make predictions about the sequence of complemen-
tary peptide (i.e. infectious) ligandswhich bind to that HLA allotype. In
fact, software programs able to predict the presence of HLA allotype
binding peptides, often known as T cell epitope prediction algorithms,
are now widely available, and have been used extensively in vaccine
design [29,30]. Whilst it is now relatively easy to identify T cell
epitopes in infections using, for example, T cell epitope mapping tools
such as TEPITOPE [31], this requires prior knowledge of the infection
and the availability of sequence information.
The obvious limitation of this approach in childhood leukemia is
that the causal infection may be any of numerous microbes to which
children are commonly exposed. Using a “reverse” approach however,
we previously reported in the UKCCS that childhood BCP ALL is
associated with alleles at the HLA-DPB1 locus, including DPB1⁎0201,
which have a glutamic acid (E) residue at position 69 of the DPβ
subunit lining the P4 peptide pocket of the DPα/β heterodimer [32].
This endows DPB1 alleles having this polymorphic residue (“DPβ69E”
alleles) with a negatively charged P4 pocket that accommodates
antigenic peptides with positively charged amino acids, such as lysine
(K), at the P4 anchor position. Since the HLA-DP locus is only weakly
linked to the DR/DQ loci, we believe that the association of BCP ALL
with DPB1⁎0201 is a primary association. Since peptide binding by
different HLA alleles can overlap in speciﬁcity, it is possible to cluster
the very large number of DP alleles (N100) into a small number of
supertypes based on predictions about their shared peptide binding
properties. In our leukemia case-control series it was possible to
cluster about 90% of the DP alleles into 6 supertypes, 3 supertypes
being DPβ69E alleles (DP2, DP6 and DP8), and 3 being DPβ69K alleles
(DP1, DP3 and DP4). We reported that the DP2 supertype is associated
with susceptibility to BCP ALL [33], whereas none of the 3 β69K
supertypes were associated with susceptibility. In fact DP1 strongly
protects against BCP ALL, possibly as a result of its ability to bind andFig. 2. Use of reverse immunogenetics to predict putative T cell epitopes (HLA-DP ligands) fr
PATSCAN search are based on amino acid residues found most frequently in pockets 1, 4, 6 an
out BLASTp searches of human viral and bacterial sequences identiﬁed by PATSCAN.present BCP ALL-associated onco-peptides such as TEL-AML1 and
AML1 to T cells [34].
To explain the infection-mediated promotion of childhood ALL,
Greaves [5] has hypothesized that a transient inﬂammatory response
mediated by cytokines selectively suppresses normal hematopoiesis,
leaving a pre-leukemia clone with a selective growth advantage. The
observed association of BCP ALL with DP2 [33] suggests that such an
inﬂammatory reaction may involve a T cell response to a limited
repertoire of infection-derived T cell epitopes. Furthermore, the
consistent association of HLA-class II alleles with autoimmune diseases
could be interpreted in the context of childhood BCP ALL as suggesting
that T cells activated by certain types of infection in children with DP2
have a greater propensity to develop auto-immunity. If the target of
this transient or chronic auto-immune response was a bone marrow
(i.e. self) antigen that was mimicked by infection, this could
accommodate the hypothesis advanced by Greaves [5].
To illustrate a possible mechanism, we cite the well-documented
example of molecular mimicry in treatment-resistant Lyme disease
(TRLD) arthritis. This is a late manifestation of Lyme disease caused by
infection with the spirochaete Borrelia burgdorferei, in which the
association with HLA-DRB1⁎0401 suggests an auto-immune etiology
[35]. Although patients with TRLD may have no evidence of B.
burgdorferei, they may have antibodies to its outer surface protein
(OspA), indicating previous exposure to the spirochaete. Identiﬁcation
of a DRB1⁎0401-binding nonamer peptide in B. burgdorferei,
OspA165–173 prompted a human peptide sequence homology search
that revealed a human lymphocyte functional antigen alphaL332–340
(LFA-1, CD11a) peptide with 6 of the 9 amino acids identical to
OspA165–173 (YVIEGTSKQ) [36]. This peptide is located in the I-region of
CD11α, a subunit that mediates the binding of LFA-1 to its ligand,
ICAM-1. Evidence that the OspA and LFA-1α peptides both bind to
DRB1⁎0401 and elicit cross-reactive T cell responses strongly suggests
that OspA165–173 mimics LFA-1a332–340 in causing TRLD [37,38].
Based on the TRLD paradigm [35], we employed a bio-informatic
approach to predict infection-derived peptides that might be
responsible for activating a DP2-restricted CD4+ T cell response
leading to BCP ALL. Diaz et al [39] have identiﬁed the principal amino
acid anchors at relative peptide positions P1, 4, 6 and 9 in natural DP2
ligands leading, in theory, to 480 potential ligands (Fig. 2). For theseom the DP2 supertype associated with childhood BCP ALL. The two ligands used in the
d 9 of DPB1⁎0201 (see text for details). HHV-5 US3 was selected empirically by carrying
Fig. 3. Schematic representation of proposed events leading to BCP ALL. Microbial
infection (HCMV?) elicits T cell response to 61FTEKHFVNV69 which cross-reacts with
CD49a (334PTEKHFFNV342) on bone marrow stroma. Although the infection is cleared by
T cell-mediated immunity [A], bone marrow stroma continues to provide chronic cross-
reactive DP2-restricted Tcell stimulation [B], thus propagating auto-immune damage to
stroma. Since pre-leukemia cells may be less dependent than normal B cell progenitors
on interactions with stroma, they have a selective growth advantage.
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including phenylalanine (F) anchored by the hydrophilic pockets 1
and 6, positively charged lysine (K) anchored by pocket 4, and valine
(V) or alanine (A) anchored by pocket 9 of DP2. These sequences give
rise to two generic peptides, FXXKXFXXV and FXXKXFXXA (where X is
an unknown amino acid residue), predicted to have a strong afﬁnity
for DP2. To identify microbial peptides with these sequences we used
the pattern-scanning algorithm, PATSCAN [40] to search the SWISS-
prot protein database [41]. This identiﬁed a total of 1013 DP2 ligands,
including peptides of human and microbial origin. Selected microbial
peptides identiﬁed in this way included Bordetella pertussis, Candida
albicans, Clostridium tetani, Escherichia coli, Haemophilus inﬂuenzae,
Helicobacter pylori, Mycobacterium tuberculosis, Mycoplasma pneumo-
niae, Staphylcoccus aureas, Variola virus and Yersina pestis. Among 4
herpes virus sequences with predicted DP2 ligands (HHV-1, -2, -5 and
-6), we selected a peptide from the HHV-5 (human cytomegalovirus)
unique short early protein, US361–69 (FTEKHFVNV) [42]. CMV is a
potential candidate agent for childhood leukemia since it is known to
elicit strong CD8+ CTL responses in asymptomatic infants, leading to
high levels of long term immunological memory [43]. Using the
US361–69 peptide sequence, we searched among non-redundant
proteins using the Basic Local Alignment Search Tool (BLASTp) [44],
for homologous human sequences. The best match was a peptide from
the inserted (I) domain of alpha 1 integrin (CD49a), αI167–175,
PTEKHFFNV which shares 7 of 9 amino acids with US361–69 [45].
The integrins are a widely expressed and diverse family of
heterodimeric adhesion receptors that play a major role in cell–
matrix and cell–cell interactions [46]. Alpha 1 integrin non-covalently
associates with beta 1 integrin to form the α1/β1 complex, VLA-1
(CD49a/CD29) which is expressed by bone marrow stromal myoﬁ-
broblasts [47]. These cells support the growth of human B cell
precursors [48] which are induced to proliferate by activated CD4+ T
cells [49]. In light of our empirical analysis, we hypothesize that early
HCMV [HHV-5] infection might lead to the development of DP2-
restricted T cells to HCMV US361–69 that can, in certain situations,
cross-react with VLA-1 αI167–175. Chronic stimulation of T cells by the
VLA-1 αI167–175 peptide after clearance of the HCMV infection could
lead to the secretion of bone-marrow suppressing cytokines, or direct
attack on stromal myoﬁbroblasts by cytotoxic T cells [50]. Either way,
this could compromise the adhesion of normal B cell progenitors to
stroma [51–53] and could account for the selective survival of pre-
leukemia cells, as envisaged by Greaves [5] (Fig. 3). Our hypothesis,
that BCP ALL arises as an indirect result of a transient auto-immune
induced inﬂammatory reaction due to molecular mimicry, might
explain why this subtype appears to be associated with delayed
infection. Children with the DP2-supertype may be at higher risk of
developing auto-immunity to a DP2-restricted T cell epitope such as
VLA-1 αI167–175, which, with some delay following clearance of the
agent, results in immune attack on bone marrow stroma.
Whilst this scenario is currently speculative, it provides a realistic
framework for further hypothesis testing involving the conﬁrmation
of HLA allele associations in childhood leukemia, in silico prediction of
HLA-restricted infectious and homologous self peptides, and the
identiﬁcation in patients of cross-reactive antibodies and memory T
cells to these non-self and self peptides. Based on the results of these
studies, it should be possible to recapitulate the impact of infection-
induced auto-immune T cells on the growth of normal and malignant
B cells in vitro in bone marrow stromal cultures to determine if the
model is correct.
MHC association mapping (NCCLS)
Recent advancements in high-throughput genotyping technolo-
gies, together with the rich genomic information provided by the
Human Genome Project and International HapMap Project initiatives,
have allowed investigators to effectively interrogate whole genomesin association studies. These approaches have been aided by the
understanding that segments of the genome are arranged into distinct
haplotype blocks deﬁned by the level of linkage disequilibrium
exhibited between neighboring genetic markers [54]. Taking advan-
tage of this knowledge, a highly speciﬁc panel of SNPs can be
assembled to represent the variation within each haplotype block,
which can then be used in combination with select known functional
SNPs and other SNPs based on linear spacing in association studies to
map regions of the genome involved in disease susceptibility.
Genome-wide mapping strategies can also be applied on a smaller
scale, for example, to cover only the xMHC region to address more
targeted hypotheses. This approach, using both case-control and
family-based study designs, has proven effective for other immune-
related complex diseases such as several classes of autoimmune
diseases including lupus [55], multiple sclerosis [23], and type 1
diabetes [22]. Despite the accumulating support for a role of
immunologic factors in the etiology of childhood leukemia [5,6], as
well as the aforementioned reports of epidemiologic associations of
childhood leukemia with speciﬁc HLA loci [32,34], no studies have yet
comprehensively reported on the mapping of associations across the
complete MHC region. Such an approach can conﬁrm previously-
reported childhood leukemia associations with speciﬁc HLA loci, help
narrow down potential causal variants within these conﬁrmed HLA
loci, and also identify new associations with other loci within the
MHC.
To begin exploring the role of genetic susceptibility behind several
of the documented immune-related associations observed between
childhood leukemia and exposure to infections and allergens, we have
initiated an association mapping project of the MHC region in the
NCCLS. Genotyping of non-Hispanic White and Hispanic subjects (the
two largest race/ethnicity populations enrolled in the NCCLS) is being
pursued using the Illumina MHC Mapping Panel (Illumina Inc., San
Diego, CA). This panel [56] comprises a highly validated series of 1293
evenly spaced SNPs spanning an approximately 4 megabase region of
the MHC bordered by the TRIM27 andMLN genes at the telomeric and
centromeric ends, respectively. There is an average 3.8 kilobase
134 M. Taylor et al. / Blood Cells, Molecules, and Diseases 42 (2009) 129–135spacing between each SNP, covering all major regions of the MHC,
including the classical class I, II and III regions, the extended class II
region and part of the extended class I region. The panel set was
designed with a strong emphasis on haplotype tagging SNPs, SNPs
that are highly informative about nearby SNPs in linkage disequili-
brium. This is a notably important feature since the chance of
detecting an association is signiﬁcantly inﬂuenced by the ability of the
SNP or combination of SNPs to adequately represent the haplotypic
diversity of the region. Higher resolution mapping is also possible, via
a second Illumina MHC speciﬁc panel, the MHC Exon-Centric Panel,
which contains 1228 SNPs and emphasizes regions near and within
coding exons. Combining the two panels yields a total of 2360 SNP
genotypes with an average 2 kilobase spacing between the SNP loci.
These Illumina MHC panels offer a cost-effective approach to scan the
MHC region. We expect that the mapping effort begun here will help
direct future efforts in selecting other speciﬁc classical class I and II
HLA loci for allelic typing and the implementation of reverse
immunogenetics methodology as described above.
It should be noted that the recent ability to test large numbers of
SNP loci in large and diverse study populations has resulted in two
major areas of concern, speciﬁcally, issues of increased probabilities of
false positive ﬁndings and population stratiﬁcation, a type of
confounding which may be present due to unaccounted population
substructure and/or recent admixture [57] in a multi-ethnic study
population. [58–60]. Whilst a statistically signiﬁcant difference in
frequency of a particular SNP or haplotype between cases and controls
provides initial evidence for a role in disease susceptibility, replication
in independent populations is required to provide credibility for the
ﬁnding and justiﬁcation for more focused study to determine the gene
and causal variants involved. In terms of false positives, in the
approach outlined here, it is important to note that the goal of
association mapping is to localize regions of interest. Individual
markers with signiﬁcant p-values are less pertinent for association
mapping than a group of neighboring markers for whom p-values are
signiﬁcant. Thus, we are not concerned with identifying variants of
interest, somuch as regions that should be explored further in this and
other study populations.
Whilst there has been a great deal of discussion regarding criteria
for establishing causality in genetic epidemiology studies [61], it is
widely agreed that replication is a critical step [62]. A result that has
been replicated in one or more study populations is unlikely to be
due solely to chance or possible population stratiﬁcation. We intend
to carefully interrogate regions identiﬁed through the MHC associa-
tion mapping effort in other comparable study populations. Such
efforts will be facilitated through the Childhood Leukemia Interna-
tional Consortium (CLIC, www.clic.berkeley.edu), a recently
assembled consortium that currently includes 14 different epide-
miologic studies of childhood leukemia representing populations
from 10 different countries including the United Kingdom, Canada,
Australia, New Zealand, France, Italy, Brazil, Germany, South Korea,
and the United States. Both the UKCCS and the NCCLS are members
this group, and plans are in progress to replicateMHC ﬁndings within
CLIC studies.
Conclusions
Technologies are now available for a detailed examination of the
role of the complete human xMHC in childhood leukemia. This will
assist the dual objectives of deﬁning the contribution of speciﬁc HLA
molecules in the natural history of childhood leukemia, and
identiﬁcation of additional xMHC genes that contribute to the disease.
The collection of comprehensive datasets on the timing and types of
environmental exposures, including several surrogate measures of
exposure to infections (e.g. daycare attendance, reported childhood
infections, birth order, etc.) [6], will facilitate an analysis of gene-
environment interactions with speciﬁc HLA alleles. Based on theresults of HLA class II molecular typing, and the central role of this
region in the pathogenesis of auto-immune disease, it is possible to
make preliminary predictions about mechanisms involving molecular
mimicry that might lead to childhood BCPALL.Whilst still in the realm
of speculation, this can be assisted by peptide pattern-scanning, and
sequence homology searches. We have selected empirically a viral
(HCMV US3) and self (alpha 1 integrin) peptide with sufﬁcient
homology to provide a hypothesis for the infection-induced suppres-
sion of normal bone marrow by molecular mimicry. Although further
modeling will identify additional candidates, and the mapping efforts
described may identify additional regions of interest in the MHC, our
hypothesis integrates the HLA molecular data with the biological
modeling of the early events in the development of childhood
leukemia, that should be testable using epidemiological and biological
methods.
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